Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Vitiligo
NCT05607316Phase 2Withdrawn
- Sponsor
- University of Massachusetts
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in Vitiligo, sponsored by University of Massachusetts. Primary endpoint: Define the different populations of cells by flow cytometry at 24 weeks. Planned start Jul 2025; status: withdrawn.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT05607316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607316.